Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained Intraoperative bleeding

被引:106
作者
Wettstein, P
Haeberli, A
Stutz, M
Rohner, M
Corbetta, C
Gabi, K
Schnider, T
Korte, W [1 ]
机构
[1] Kantonsspital, Inst Clin Chem & Hematol, CH-9007 St Gallen, Switzerland
[2] Kantonsspital, Dept Anesthesiol, CH-9007 St Gallen, Switzerland
[3] Univ Bern, Dept Clin Res, Bern, Switzerland
关键词
D O I
10.1213/01.ANE.0000134800.46276.21
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
To explore relevant changes in unexplained intraoperative bleeding, we evaluated elements of the final steps of the coagulation cascade in 226 consecutive patients undergoing elective surgery. Patients were stratified for the occurrence of unexplained intraoperative bleeding according to predefined criteria. Twenty patients (8.8%) developed unexplained bleeding. The median intraoperative blood loss was 1350 mL (bleeders) and 400 mL (nonbleeders) (P < 0.001). Fibrinogen and Factor XIII (F. XIII) were more rapidly consumed in bleeders (P < 0.001). Soluble fibrin formation (fibrin monomer) was increased in bleeders throughout surgery (P less than or equal to 0.014). However, F. XIII availability per unit thrombin generated was significantly decreased in bleeders before, during, and after surgery (P less than or equal to 0.051). Computerized thrombelastography showed a parallel, significant reduction in clot firmness. We suggest that mild preexisting coagulopathy is not rare in surgical patients and probably can result in clinically relevant intraoperative bleeding. This hemostatic disorder shows impaired clot firmness, probably secondary to decreased cross-linking (due to a loss of F. XIII, both in absolute measures and per unit thrombin generated). We suggest that the application of F. XIII might be worthwhile to test in a prospective clinical trial to increase clot firmness in patients at risk for this intraoperative coagulopathy.
引用
收藏
页码:1564 / 1569
页数:6
相关论文
共 25 条
[1]  
CALATZIS A, 1995, ANAESTHESIST, V44, P491
[2]  
CALATZIS A, 1996, ANN HEMATOL, V72, P90
[3]   DETERMINANTS OF BLOOD UTILIZATION DURING MYOCARDIAL REVASCULARIZATION [J].
COSGROVE, DM ;
LOOP, FD ;
LYTLE, BW ;
GILL, CC ;
GOLDING, LR ;
TAYLOR, PC ;
FORSYTHE, SB .
ANNALS OF THORACIC SURGERY, 1985, 40 (04) :380-384
[4]   Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery [J].
Dunne, JR ;
Malone, D ;
Tracy, JK ;
Gannon, C ;
Napolitano, LM .
JOURNAL OF SURGICAL RESEARCH, 2002, 102 (02) :237-244
[5]  
EGBRING R, 1993, FACTOR 13, P217
[6]  
Egbring Rudolf, 1996, Seminars in Thrombosis and Hemostasis, V22, P419, DOI 10.1055/s-2007-999041
[7]   Relationship between clinical history, coagulation tests, and perioperative bleeding during tonsillectomies in pediatrics [J].
Gabriel, P ;
Mazoit, X ;
Ecoffey, C .
JOURNAL OF CLINICAL ANESTHESIA, 2000, 12 (04) :288-291
[8]   Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures [J].
Gerlach, R ;
Raabe, A ;
Zimmermann, M ;
Siegemund, A ;
Seifert, V .
SURGICAL NEUROLOGY, 2000, 54 (03) :260-264
[9]   The effect of Factor XIII on bleeding in coronary surgery [J].
Gödje, O ;
Haushofer, M ;
Lamm, P ;
Reichart, B .
THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (05) :263-267
[10]  
GRUNEWALD M, 1993, Z KARDIOL, V82, P129